Figure 2. Kaplan Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy).

Tick marks represent patients at the time of censoring, and P values were calculated using log-rank (Mantel-Cox) test. For a similar analysis by TMB low vs. intermediate to high, see Supplemental Figure 2.

Panel A: PFS for patients with all tumor types excluding melanoma and NSCLC – TMB low to intermediate vs. high [P = 0.0033, HR = 0.35 (95% CI 0.19 to 0.64)]. For TMB low to intermediate, N = 40 with 35 events. For TMB high, N = 15 with 8 events.

Panel B: PFS for patients with all tumor types including melanoma and NSCLC – TMB low to intermediate vs. high [P = 0.0005, HR = 0.36 (95% CI 0.23 to 0.58)]. For TMB low to intermediate, N = 80, with 66 events. For TMB high, N = 22 with 12 events.

Panel C: PFS for patients with melanoma or NSCLC – TMB low to intermediate vs. high [P = 0.0402, HR = 0.36 (95% CI 0.17 to 0.77)]. For TMB low to intermediate, N = 40 with 31 events. For TMB high, N = 7 with 4 events.

Panel D: OS for patients with all tumor types excluding melanoma and NSCLC – TMB low to intermediate vs. high for all tumor types excluding melanoma and NSCLC [P = 0.2836, HR = 0.59 (95% CI 0.25 to 1.40]. For TMB low to intermediate, N = 40 with 20 events. For TMB high, N = 15 with 5 events.

Panel E: OS for patients with all tumor types including melanoma and NSCLC – TMB low to intermediate vs. high [P = 0.0557, HR = 0.44 (95% CI 0.23 to 0.87)]. For TMB low to intermediate, N = 80 with 36 events. For TMB high, N = 22 with 6 events.

Panel F: OS for patients with melanoma or NSCLC – TMB low to intermediate vs. high [P = 0.0926, HR = 0.21 (95% CI 0.07 to 0.63)]. For TMB low to intermediate, N = 40 with 16 events. For TMB high, N = 7 with 1 events.

Abbreviations: CI = confidence interval; HR = hazard ratio; NSCLC = non-small cell lung cancer; OS = overall survival; PD-1 = programmed death receptor-1; PD-L1 = programmed death receptor-ligand 1; PFS = progression free survival; TMB = tumor mutational burden